Allogene Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a U.S.-based biotechnology company listed on the NASDAQ under the ticker ALLO, with headquarters in South San Francisco, California, United States. The company develops allogeneic CAR-T cell therapies, meaning “off-the-shelf” cancer treatments made from donor cells rather than patient-specific cells. For French-speaking investors in Europe, it represents a specialized high-innovation healthcare name positioned in advanced cell therapy, with exposure to oncology and, increasingly, autoimmune disease applications. Founded in 2017, Allogene was built around a clear strategic thesis: to industrialize the next generation of CAR-T by reducing the logistical complexity, turnaround time, and manufacturing bottlenecks associated with autologous therapies. The company emphasizes a team of cell-therapy veterans and a platform designed to deliver more standardized therapies that can be administered on demand and, over time, scaled more efficiently across larger patient populations. As a development-stage biotech, its business model is driven less by current revenue generation and more by clinical progress, regulatory milestones, and the ability to fund long research and development timelines. Allogene’s core pipeline is focused on allogeneic CAR-T product candidates, primarily in hematologic malignancies. Its lead asset, cema-cel (cemacabtagene ansegedleucel), has been a major market focal point, particularly in diffuse large B-cell lymphoma and related blood-cancer settings. The company is also advancing platform technologies aimed at improving cell engineering, persistence, and safety, while exploring broader opportunities in autoimmune disease. In a highly competitive landscape that includes large pharmaceutical companies, CAR-T developers, and other emerging cell-therapy platforms, Allogene differentiates itself through its off-the-shelf manufacturing concept and the potential for broader patient access. Geographically, Allogene remains anchored in the United States, with operations centered in California, while its clinical strategy uses multicenter and, in some cases, international trial sites. Recent highlights include continued development of the pivotal ALPHA3 program, the expansion of that trial into additional countries, and a meaningful capital raise announced in spring 2026. These developments underscore the company’s effort to advance its pipeline while strengthening its balance sheet, which is critical for a pre-commercial biotech. For investors, ALLO is therefore a high-upside but high-risk healthcare stock, where long-term value creation depends heavily on clinical execution, regulatory progress, and sustained financing capacity.